Safety and immunogenicity of a first dose of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic stem-cells recipients.
Patrice ChevallierMarianne Coste-BurelAmandine Le BourgeoisPierre PeterlinAlice GarnierMarie C BénéBerthe-Marie ImbertThomas DrumelSteven Le GouillPhilippe MoreauBeatrice MaheViviane DubruilleNicolas BlinAnne LokCyrille TouzeauThomas GastinneMaxime JullienSophie VanthygemThierry GuillaumePublished in: EJHaem (2021)
This was a monocentric prospective study testing the efficacy and safety of a first injection of BNT162b2 (Pfizer-BioNTech) in 112 Allo-HSCT patients. Antibody response to SARS-CoV-2 spike protein receptor-binding domain was tested at the time of the second injection (Roche Elecsys). The study also included a non-randomized control arm of 26 healthy controls. This study shows that a first dose of SARS-CoV-2 messenger RNA vaccine is safe and provides a 55% rate of seroconversion in allotransplanted patients compared to 100% for the controls (p < 0.001). Factors influencing the absence of response in patients were recent transplantation (<2 years), lymphopenia (<1 × 109/L) and immunosuppressive treatment or chemotherapy at the time of vaccination.
Keyphrases
- sars cov
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- stem cells
- squamous cell carcinoma
- randomized controlled trial
- open label
- small molecule
- coronavirus disease
- clinical trial
- cell death
- low dose
- respiratory syndrome coronavirus
- smoking cessation
- phase iii
- cell therapy
- placebo controlled
- dna binding
- nucleic acid